OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
QLINEA$18.2058

Q linea AB

Advanced Medical Equipment & TechnologyVerified

Q linea AB has a market price of 18.2 SEK and a market capitalization of 344,867,286.4 SEK. The company's price-to-book ratio is 5.06, and its price-to-tangible-book ratio is also 5.06. The enterprise value to EBITDA ratio is -5.83, indicating a negative EBITDA, and the enterprise value to revenue ratio is 2,396.18. The company's liquidity position is assessed as medium, with a current ratio of 1.19 and negative net cash after subtracting total debt. The company's profitability metrics are negative, with a return on equity of -0.9657 and a return on assets of -0.4137. The debt-to-equity ratio is 0.84, suggesting a moderate level of leverage. The operating cash flow is -92,088,000 SEK, and the free cash flow is -65,343,000 SEK, indicating significant cash outflows. Q linea AB's revenue is 159,000,000 SEK, and its gross profit is -27,300,000 SEK. The operating income is -65,374,000 SEK, and the net income is -65,774,000 SEK, showing substantial losses. The capital expenditure is -6,519,000 SEK, indicating ongoing investment in capital assets. The company's growth trajectory is uncertain, with a mean revenue estimate of 107,000,000 SEK and a mean EBIT estimate of -99,000,000 SEK. The last actual revenue was 11,098,000 SEK, and the last actual EPS was -27.40 SEK. The mean price target is 50.00 SEK, significantly higher than the current market price. The risk assessment indicates a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash after subtracting total debt, which could impact the company's ability to meet short-term obligations. Recent financial observations show that the company is experiencing significant financial challenges, with negative operating and net income, and a high price-to-revenue ratio. The company's financial health is a concern, and it may need to address its cash flow and profitability issues to sustain operations.

30-day price · QLINEA-7.57 (-32.8%)
Low$15.30High$28.90Close$15.50As of12 May, 00:00 UTC
Profile
CompanyQ linea AB
TickerQLINEA.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Q linea AB is a healthcare equipment company that develops and sells advanced medical equipment and technology.

Classification. Q linea AB is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

Q linea AB has a market price of 18.2 SEK and a market capitalization of 344,867,286.4 SEK. The company's price-to-book ratio is 5.06, and its price-to-tangible-book ratio is also 5.06. The enterprise value to EBITDA ratio is -5.83, indicating a negative EBITDA, and the enterprise value to revenue ratio is 2,396.18. The company's liquidity position is assessed as medium, with a current ratio of 1.19 and negative net cash after subtracting total debt. The company's profitability metrics are negative, with a return on equity of -0.9657 and a return on assets of -0.4137. The debt-to-equity ratio is 0.84, suggesting a moderate level of leverage. The operating cash flow is -92,088,000 SEK, and the free cash flow is -65,343,000 SEK, indicating significant cash outflows. Q linea AB's revenue is 159,000,000 SEK, and its gross profit is -27,300,000 SEK. The operating income is -65,374,000 SEK, and the net income is -65,774,000 SEK, showing substantial losses. The capital expenditure is -6,519,000 SEK, indicating ongoing investment in capital assets. The company's growth trajectory is uncertain, with a mean revenue estimate of 107,000,000 SEK and a mean EBIT estimate of -99,000,000 SEK. The last actual revenue was 11,098,000 SEK, and the last actual EPS was -27.40 SEK. The mean price target is 50.00 SEK, significantly higher than the current market price. The risk assessment indicates a medium liquidity risk and a low dilution risk. The key financial flag is the negative net cash after subtracting total debt, which could impact the company's ability to meet short-term obligations. Recent financial observations show that the company is experiencing significant financial challenges, with negative operating and net income, and a high price-to-revenue ratio. The company's financial health is a concern, and it may need to address its cash flow and profitability issues to sustain operations.
Key takeaways
  • Q linea AB is experiencing significant financial losses, with a net income of -65,774,000 SEK.
  • The company's liquidity position is medium, with a current ratio of 1.19 and negative net cash after subtracting total debt.
  • The enterprise value to revenue ratio is 2,396.18, indicating a high valuation relative to revenue.
  • Analysts have set a mean price target of 50.00 SEK, which is significantly higher than the current market price of 18.2 SEK.
  • The company's profitability metrics are negative, with a return on equity of -0.9657 and a return on assets of -0.4137.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$159.0k
Gross profit-$2.7M
Operating income-$65.4M
Net income-$65.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$92.1M
CapEx-$6.5M
Free cash flow-$65.3M
Total assets$159.0M
Total liabilities$90.9M
Total equity$68.1M
Cash & equivalents$20.9M
Long-term debt$57.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$9.3M-$232.0M-$231.4M-$435.4M
FY-3$12.8M-$262.2M-$268.7M-$282.7M
FY-2$4.4M-$230.6M-$229.4M-$220.2M
FY-1$2.4M-$213.6M-$216.9M-$204.2M
FY0$11.1M-$176.7M-$182.5M-$177.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$484.5M$430.5M$15.1M
FY-3$229.9M$163.2M$72.9M
FY-2$232.0M$189.6M$81.9M
FY-1$148.0M-$27.5M$25.7M
FY0$369.7M$338.0M$258.1M
PeriodOCFCapExFCFSBC
FY-4-$249.2M-$216.2M-$435.4M
FY-3-$250.9M-$29.2M-$282.7M
FY-2-$228.5M-$8.3M-$220.2M
FY-1-$182.5M-$5.0M-$204.2M
FY0-$162.1M-$7.7M-$177.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$159.0k-$65.4M-$65.8M-$65.3M
FQ-6$569.0k-$41.1M-$42.4M-$36.7M
FQ-5$158.0k-$51.2M-$52.8M-$48.5M
FQ-4$3.7M-$44.6M-$45.2M-$41.2M
FQ-3$1.1M-$47.3M-$48.2M-$49.3M
FQ-2$3.5M-$40.7M-$42.2M-$41.1M
FQ-1$2.9M-$44.1M-$46.9M-$45.8M
FQ0$2.0M-$35.0M-$33.6M-$32.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$159.0M$68.1M$20.9M
FQ-6$138.6M$25.7M$7.5M
FQ-5$148.0M-$27.5M$25.7M
FQ-4$193.9M$120.0M$68.0M
FQ-3$201.0M$129.5M$82.7M
FQ-2$155.4M$87.5M$42.6M
FQ-1$369.7M$338.0M$258.1M
FQ0$333.6M$304.4M$223.9M
PeriodOCFCapExFCFSBC
FQ-7-$92.1M-$6.5M-$65.3M
FQ-6-$142.1M-$5.0M-$36.7M
FQ-5-$182.5M-$5.0M-$48.5M
FQ-4-$50.1M-$195.0k-$41.2M
FQ-3-$85.4M-$5.2M-$49.3M
FQ-2-$122.3M-$7.7M-$41.1M
FQ-1-$162.1M-$7.7M-$45.8M
FQ0-$30.2M-$2.4M-$32.0M
Valuation
Market price$18.20
Market cap$344.9M
Enterprise value$381.0M
P/E
Reported non-GAAP P/E
EV/Revenue2396.2
EV/Op income
EV/OCF
P/B5.1
P/Tangible book5.1
Tangible book$68.1M
Net cash-$36.1M
Current ratio1.2
Debt/Equity0.8
ROA-41.4%
ROE-96.6%
Cash conversion1.4%
CapEx/Revenue-41.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricQLINEAActivity
Op margin-41115.7%-16.5% medp25 -174.5% · p75 8.8%bottom quartile
Net margin-41367.3%-16.5% medp25 -172.4% · p75 8.4%bottom quartile
Gross margin-1717.0%47.4% medp25 34.2% · p75 65.3%bottom quartile
CapEx / revenue-4100.0%-5.4% medp25 -12.5% · p75 -2.2%bottom quartile
Debt / equity84.0%4.3% medp25 0.0% · p75 28.0%top quartile
Observations
IR observations
Mean price target50.00 SEK
Median price target50.00 SEK
High price target50.00 SEK
Low price target50.00 SEK
Last actual EPS-27.40 SEK
Mean revenue estimate107,000,000 SEK
Last actual revenue11,098,000 SEK
Mean EBIT estimate-99,000,000 SEK
Social pillar26.77 (0-100)
Governance pillar15.13 (0-100)
ESG controversies score100.00 (0-100, higher = fewer controversies)
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 19:35 UTC#db1a2f03
Market quoteclose SEK 15.50 · shares 0.02B diluted
no public URL
2026-05-12 00:42 UTC#7059a1c8
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 03:07 UTCJob: 96f06074